DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Evacetrapib is an investigational drug.
There have been 21 clinical trials for Evacetrapib. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemias. The leading clinical trial sponsors are Eli Lilly and Company, The Cleveland Clinic, and [disabled in preview].
There are ninety-two US patents protecting this investigational drug and seven hundred and thirty-nine international patents.
Recent Clinical Trials for Evacetrapib
|A Study of Different Particle Sizes of Evacetrapib in Healthy Participants||Eli Lilly and Company||Phase 1|
|A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia||Eli Lilly and Company||Phase 3|
|A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants||Eli Lilly and Company||Phase 1|
Top disease conditions for Evacetrapib
Top clinical trial sponsors for Evacetrapib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Evacetrapib||Get Started Free||Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein||Merck Sharp & Dohme Corp. (Rahway, NJ)||Get Started Free|
|Evacetrapib||Get Started Free||Soluble guanylate cyclase stimulators||Merck Sharp & Dohme Corp. (Rahway, NJ)||Get Started Free|
|Evacetrapib||Get Started Free||Antidiabetic compounds||Merck Sharp & Dohme Corp. (Rahway, NJ)||Get Started Free|
|Evacetrapib||Get Started Free||[5,6]--fused bicyclic antidiabetic compounds||Merck Sharp & Dohme Corp. (Rahway, NJ)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Evacetrapib||European Patent Office||EP3174537||2034-07-29||Get Started Free|
|Evacetrapib||World Intellectual Property Organization (WIPO)||WO2016018729||2034-07-29||Get Started Free|
|Evacetrapib||Argentina||AR107154||2035-12-22||Get Started Free|
|Evacetrapib||Australia||AU2016377364||2035-12-22||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|